Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Capital Expenditures of $1.0 million for Q1 2026, little changed year-over-year from $1.0 million in Q1 2025, and up 6.61% quarter-over-quarter from $938000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Capital Expenditures for 14 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures changed 0.0% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $6.0 million (down 59.24% YoY), while the FY2025 annual figure was $6.0 million, down 60.0% from the prior year.
- Capital Expenditures improved to $1.0 million in Q1 2026 per RARE's latest filing, from $938000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $95.7 million in Q4 2022 and bottomed at -$42.7 million in Q3 2022.
- Historically, Capital Expenditures has averaged $8.7 million across 5 years, with a median of $2.8 million in 2025.
- Annual changes were most pronounced in 2022 — Capital Expenditures plunged 307.55% — and 2025, when it jumped 830.71%.
- Ultragenyx Pharmaceutical's Capital Expenditures stood at $95.7 million in 2022, then slumped by 134.14% to -$32.7 million in 2023, then surged by 124.99% to $8.2 million in 2024, then tumbled by 88.51% to $938000.0 in 2025, then climbed by 6.61% to $1.0 million in 2026.
- Business Quant data shows RARE's Capital Expenditures at $1.0 million in Q1 2026, $938000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 938,000.00 |
| Dec 31, 2025 | 938,000.00 |
| Sep 30, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 8.16 Mn |
| Dec 31, 2024 | 8.16 Mn |
| Sep 30, 2024 | 5.94 Mn |
| Sep 30, 2024 | 5.94 Mn |
| Jun 30, 2024 | -381,000.00 |
| Jun 30, 2024 | -381,000.00 |
| Mar 31, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.28 Mn |